[Detection and diagnosis of chronic kidney disease to take action as early as stage 3].

DETECTION AND DIAGNOSIS OF CHRONIC KIDNEY DISEASE TO TAKE ACTION AS EARLY AS STAGE 3. The prevalence of chronic kidney disease (CKD) is constantly increasing. The considerable impact of CKD on all-cause mortality, cardiovascular morbidity and on health economy makes it a real public health issue. Early detection helps to prevent progression to advanced stages of the disease. Targeted screening in populations at risk is recommended, with the use of 3 tests: serum creatinine, estimation of GFR and measurement of albumin/creatinine ratios. Once diagnosed, management of CKD involves nephroprotective measures such as blood pressure management, correction of metabolic complications, and prevention of drug toxicity. The general practitioner has a central role in the screening and initial management of CKD.
Competing Interests: L’auteure déclare avoir perçu ou percevoir une rémunération en provenance d’une entreprise commerciale directement ou indirectement liée au sujet développé dans cet article. Honoraires en tant qu’orateur par AstraZeneca, membre du Board Boehringer Ingelheim.